185968-90-5 Usage
Uses
Used in Chemical Synthesis:
Z-D-DAP(FMOC)-OH is used as a building block in the synthesis of peptide-based compounds, leveraging its dipeptide structure and carboxylic acid group for the creation of complex molecular architectures.
Used in Research and Development:
In the field of chemical and biological research, Z-D-DAP(FMOC)-OH is used as a fluorescent labeling reagent, taking advantage of the FMOC tag to track and visualize molecules in various experimental setups.
Used in Bacterial Cell Wall Studies:
Z-D-DAP(FMOC)-OH is utilized as a tool for studying the biosynthesis of bacterial cell walls, given its structural similarity to diaminopimelic acid, a key component in the cell wall's integrity.
Used in Pharmaceutical Development:
Given its potential interactions with bacterial cell wall components, Z-D-DAP(FMOC)-OH may be explored as a precursor in the development of new antibiotics or other pharmaceuticals targeting bacterial infections.
Used in Bioconjugation and Drug Delivery:
The carboxylic acid group in Z-D-DAP(FMOC)-OH allows for its use in bioconjugation, where it can be linked to other biomolecules or drug molecules for targeted drug delivery applications.
Used in Diagnostics:
The fluorescent properties of the FMOC tag in Z-D-DAP(FMOC)-OH can be employed in diagnostic assays, where the compound can serve as a marker for detecting specific biological interactions or processes.
Check Digit Verification of cas no
The CAS Registry Mumber 185968-90-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,5,9,6 and 8 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 185968-90:
(8*1)+(7*8)+(6*5)+(5*9)+(4*6)+(3*8)+(2*9)+(1*0)=205
205 % 10 = 5
So 185968-90-5 is a valid CAS Registry Number.
185968-90-5Relevant articles and documents
Total synthesis of quinaldopeptin and its analogues
Ichikawa, Satoshi,Okamura, Takuya,Matsuda, Akira
, p. 12662 - 12670 (2013)
The first total synthesis of quinaldopeptin (1) was accomplished. Our approach to the synthesis of 1 includes the solid-phase peptide synthesis of the linear decapeptide 4 followed by macrocyclization and introduction of the quinoline chromophores 2 at a late stage of the synthesis. As for the preparation of 4, a fragment coupling approach was applied considering the C2 symmetrical structure of 1. Chromophore analogues 22 and 23 and desmethyl analogue 27 were also prepared in a manner similar to the synthesis of 1. Synthetic 1 exhibits a strong cytotoxicity with the IC50 value of 3.2 nM. On the other hand, the activity of 23 and 27 was largely reduced.
BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS
-
Page/Page column 26-27, (2008/06/13)
The present invention provides compounds having formula (I) wherein n, p, q and r are each independently selected from 0 or 1; a, b, c, and d each independently represents a carbon or nitrogen atom, with the proviso that no more than two of a, b, c, and d are nitrogen atoms; Y and Y' each independently represents 1-4 optional substituents selected from alkyl, alkoxy, halo, -CF3, and -C(O)OH; R, R, R and R are H or specified substituents; R, R, R, R, R, R, R and R are independently selected from H or C1-C3 alkyl; or a biolabile ester thereof, or a pharmaceutically acceptable salt thereof. Also provided are methods of using these compounds for treating vitronectin-mediated disorders, e.g., cancer, retinopathy, artherosclerosis, vascular restenosis, and osteoporosis.
